Previous 10 | Next 10 |
Image source: The Motley Fool. Flexion Therapeutics Inc (NASDAQ: FLXN) Q4 2020 Earnings Call Mar 10, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Flexion Therapeutics Inc (FLXN) Q4 2020 Earnings Call Transcript ...
Flexion Therapeutics, Inc. (FLXN) Q4 2020 Earnings Conference Call March 10, 2021 4:30 PM ET Company Participants Scott Young - Vice President of Corporate Communications & Investor Relations Michael Clayman - Chief Executive Officer Melissa Layman - Chief Commercial Officer David Arkowit...
Flexion Therapeutics (FLXN): FY GAAP EPS of -$2.53 beats by $0.10.Revenue of $85.55M (+17.3% Y/Y) misses by $0.19M.Company reported ZILRETTA® net sales of $85.6 million for full-year 2020 representing 17% growth over 2019.First patient treated in high dose cohort of Phase ...
Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $85.6 million for full-year 2020 representing 17% growth over 2019 First patient treated in high dose cohort of Phase 1 clinical trial evaluatin...
BURLINGTON, Mass., March 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its fourth-quarter and full-year 2020 financial results after the close of the U.S. financial markets on Wednesday, March 10, 2021. A live webcast of the ...
The FDA has cleared Flexion Therapeutics' (FLXN) Investigational New Drug ((IND)) application for FX301, a locally administered NaV1.7 inhibitor known as funapide, formulated for extended-release in a thermosensitive hydrogel.Funapide has the potential to provide effective non-opioid pain rel...
FX301 combines NaV1.7 inhibitor (funapide) with a proprietary thermosensitive hydrogel to facilitate administration as a peripheral analgesic nerve block FX301 may provide 3 to 5 days of non-opioid pain relief while preserving motor function following musculoskeletal surgery ...
BURLINGTON, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the 42 nd Annual Raymond James Institutional Investors Con...
First-in-human single ascending dose trial advances to high dose cohort following positive Data Monitoring Committee review of mid dose safety data Company to expand FX201 low dose and mid dose cohorts to include up to 20 additional patients in each treatment group Fle...
CHICAGO and BURLINGTON, Mass., Feb. 01, 2021 (GLOBE NEWSWIRE) -- The National Basketball Retired Players Association (NBRPA) and Flexion Therapeutics Inc. today announced a new partnership to raise awareness of osteoarthritis-related knee pain and present ZILRETTA (triamcinolone acetonide e...
News, Short Squeeze, Breakout and More Instantly...
Flexion Therapeutics Inc. Company Name:
FLXN Stock Symbol:
NASDAQ Market:
Flexion Therapeutics Inc. Website:
-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway -- TAMPA, Fla. and BURLINGTON, Mass., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc...